<DOC>
	<DOCNO>NCT02442531</DOCNO>
	<brief_summary>The goal Phase1 clinical research study find high safe dose CriPec® docetaxel give treatment patient solid tumour .</brief_summary>
	<brief_title>A Study CriPec® Docetaxel Given Patients With Solid Tumours</brief_title>
	<detailed_description>The study design explore safety , tolerability , pharmacokinetics pharmacodynamics CriPec® docetaxel identify Maximum Tolerated Dose ( MTD ) .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . At least 18 year old 2 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 3 . Estimated life expectancy least 12 week 4 . Ability willingness give write informed consent comply requirement study For Part 1 : 5 . Patients pathologically confirm diagnosis advance , recurrent progressive solid tumour refractory standard therapy standard therapy exist measurable evaluable disease accord RECIST 1.1 . For Part 2 : 6 . Patients pathologically confirm diagnosis advance , recurrent progressive cancer measurable disease accord RECIST 1.1 histological type refractory standard therapy standard therapy exist treatment taxane appropriate treatment option . 1 . Less 4 week since last treatment chemotherapy , biological therapy , immunotherapy systemic radiotherapy ( except palliative radiation deliver &lt; 20 % bone marrow ) , less 6 week nitrosoureas mitomycin C prior Cycle 1 Day 1 . 2 . Current recent ( within 4 week prior Cycle 1 Day 1 ) treatment another Investigational Product participation another investigational interventional study . 3 . Symptomatic brain metastasis . 4 . Toxicities incur result previous anticancer therapy ( radiation therapy , chemotherapy , surgery ) resolve ≤ grade 2 ( define CTCAE version 4.03 ) . 5 . Inadequate bone marrow function screen evidence follow : Absolute Neutrophil Count ( ANC ) &lt; 1.5 x 109/L . Platelet count &lt; 100 x 109/L . Haemoglobin &lt; 6.0 mmol/L ( &lt; 9.6 g/dL ) . The patient receive transfusion growth factor abnormalities 7 day prior Cycle 1 Day 1 . 6 . Serum ( total ) bilirubin &gt; 1.5 x Upper Limit Normal ( ULN ) institution liver metastasis ( &gt; 2 x ULN patient liver metastasis ) . 7 . AST ALT &gt; 2.5 x ULN liver metastasis ( &gt; 5x ULN patient liver metastasis ) . 8 . Alkaline phosphatase level &gt; 2.5 x ULN liver metastasis ( &gt; 5 x ULN patient liver metastasis , &gt; 10 x ULN patient bone metastasis ) . 9 . Increased plasma prothrombin time International Normalized Ratio ( INR ) , consequence reduce hepatic production Vitamin K. 10 . Hepatitis B surface antigen hepatitis C positivity abnormal liver function test . 11 . Medical history : Nonalcoholic steatohepatitis ( NASH ) . History human immunodeficiency virus ( HIV ) antibody positive use antiretroviral therapy . Alcoholic autoimmune hepatitis . Ischemic hepatitis , Cardiovascular dysfunction impair liver oxygenation , include hypotension right heart failure . 12 . Serum creatinine &gt; 1.5 x ULN . 13 . Estimated Glomerular Filtration Rate &lt; 50 mL/min/1.73m2 calculate Modification Diet Renal Disease ( MDRD ) formula creatinine clearance &lt; 50 mL/min calculate CockcroftGault . 14 . Stroke within 6 month prior Cycle 1 Day 1 . 15 . Transient Ischemic Attack ( TIA ) within 6 month prior Cycle 1 Day 1 . 16 . Myocardial infarction within 6 month prior Cycle 1 Day 1 . 17 . Unstable angina . 18 . New York Heart Association ( NYHA ) Grade II great Congestive Heart Failure screen . 19 . Serious cardiac arrhythmia require medication . 20 . Patients pregnant breastfeeding . 21 . Absence effective mean contraception female patient childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) male patient surgically sterile female partner childbearing potential . 22 . Major surgical procedure ( include open biopsy exclude central line intravenous catheter ) within 28 day prior first study treatment , anticipation need major surgery course study treatment . 23 . Grade ≥2 motor sensory neuropathy symptom ( define CTCAE version 4.03 ) . 24 . Known hypersensitivity Investigational Product 's excipients taxanes . 25 . History drug alcohol abuse opinion investigator within 3 year screen . 26 . Evidence medical condition ( psychiatric illness , infectious disease , physical examination laboratory finding ) may interfere plan treatment , affect patient compliance place patient high risk treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>